Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Pills Allowed Limited Size Differential In Draft Guidance

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA cites concern about safety and patient adherence to therapy in draft guidance on the size, shape and other physical attributes of generic drugs.

You may also be interested in...



FDA Rejects Generic Tablets Larger Than Brand Citing Safety And Efficacy Concerns

FDA denies ANDAs for one product because the generic tablet size is larger than the brand; the agency plans to release a draft guidance on generic equivalency to the reference listed drug in size, taste and smell.

ANDA User Fees Will Fund Public Relations-focused Studies On Palatability Of Generics

One project will look at tablet size, odor and other characteristics that in the past have been a source of public complaints about generics.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS075141

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel